Skip to main content
Top
Published in: Osteoporosis International 10/2017

Open Access 01-10-2017 | Original Article

Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data

Authors: F. Xue, V. Goli, P. Petraro, T. McMullan, J. M. Sprafka, E. J. Tchetgen Tchetgen

Published in: Osteoporosis International | Issue 10/2017

Login to get access

Abstract

Summary

Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be causing time-varying confounding. BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model versus the weighted MSM. The discrepancy of effect estimates for overall infection in the MSM suggested there may be time-varying confounding.

Introduction

Due to the suboptimal persistence to osteoporosis (OP) treatment, factors triggering treatment discontinuation/switching may be affected by prior treatment and confound the subsequent treatment effect, causing time-varying confounding.

Methods

In a US insurance database, the association between joint treatment of bisphosphonates (BP) and other OP medication and the incidence of infections among postmenopausal women was assessed using a marginal structural model (MSM). Stabilized weights were estimated by modeling treatment and censoring processes conditioning on past treatment, and baseline and time-varying covariates.

Results

BP treatment was associated with the risk of overall infection in opposite directions in the unweighted Cox model {incidence rate ratio [IRR] [95% confidence interval (CI)] = 1.15 [1.14–1.17]} versus the weighted MSM [IRR (95% CI) = 0.79 (0.77–0.81)], but was consistently associated with a lower risk of serious infection in both the unweighted Cox model [IRR (95% CI] = 0.79 (0.78–0.81)) and the weighted MSM [IRR (95% CI) = 0.71 (0.68–0.75)]. Similar results were found when current and past treatments were simultaneously assessed.

Conclusions

The discrepancy of effect estimates for overall but not serious infection comparing unweighted models and MSM suggested analyses of composite outcomes with a wide range of disease severity may be more susceptible to time-varying confounding.
Appendix
Available only for authorised users
Literature
1.
go back to reference DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (2005) Pharmacotherapy: a pathophysiologic approach. McGraw-Hill, New York DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (2005) Pharmacotherapy: a pathophysiologic approach. McGraw-Hill, New York
3.
go back to reference Chang JI, Hazboun RC, Chang TI (2014) Incongruities in the AAOMS Position Paper: Medication-Related Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg 72(12):2381CrossRefPubMed Chang JI, Hazboun RC, Chang TI (2014) Incongruities in the AAOMS Position Paper: Medication-Related Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg 72(12):2381CrossRefPubMed
5.
go back to reference Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson J (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45:843–852CrossRefPubMed Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson J (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45:843–852CrossRefPubMed
6.
go back to reference Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652CrossRefPubMed Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652CrossRefPubMed
7.
go back to reference Robins, J. (1998) Marginal structural models. 1997 Proceedings of the American Statistical Association. Section on Bayesian Statistical Science, pp. 1–10. Reproduced courtesy of the American Statistical Association Robins, J. (1998) Marginal structural models. 1997 Proceedings of the American Statistical Association. Section on Bayesian Statistical Science, pp. 1–10. Reproduced courtesy of the American Statistical Association
8.
go back to reference Robins JM, Rotnitzky A, Zhao LP (1994) Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 89:846–866CrossRef Robins JM, Rotnitzky A, Zhao LP (1994) Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 89:846–866CrossRef
9.
go back to reference Hernan MA, Robins JM (2010) Causal inference, Chapman & Hall/CRC monographs on statistics & applied probability, CRC, p. 70, ISBN 1-4200-7616-7 Hernan MA, Robins JM (2010) Causal inference, Chapman & Hall/CRC monographs on statistics & applied probability, CRC, p. 70, ISBN 1-4200-7616-7
10.
go back to reference Greenland S, Pearl J, Robins JM (1999 Jan) Causal diagrams for epidemiologic research. Epidemiology 10(1):37–48CrossRefPubMed Greenland S, Pearl J, Robins JM (1999 Jan) Causal diagrams for epidemiologic research. Epidemiology 10(1):37–48CrossRefPubMed
11.
go back to reference Pearl J (2009) Causality: Models, Reasoning and Inference, 2nd edn. Cambridge University Press, CambridgeCrossRef Pearl J (2009) Causality: Models, Reasoning and Inference, 2nd edn. Cambridge University Press, CambridgeCrossRef
12.
go back to reference Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550–560CrossRefPubMed Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550–560CrossRefPubMed
13.
go back to reference Hernán MA, Brumback BA, Robins JM (2002) Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21(12):1689–1709CrossRefPubMed Hernán MA, Brumback BA, Robins JM (2002) Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 21(12):1689–1709CrossRefPubMed
14.
go back to reference Hernán MA, Brumback B, Robins JM (2001) Marginal structural models to estimate the joint causal effect of non-randomized treatments. JASA 96:440–448CrossRef Hernán MA, Brumback B, Robins JM (2001) Marginal structural models to estimate the joint causal effect of non-randomized treatments. JASA 96:440–448CrossRef
15.
go back to reference Tonti E (2013) Jiménez de Oya N, Galliverti G, Moseman EA, Di Lucia P, Amabile A, Sammicheli S, De Giovanni M, Sironi L, Chevrier N, Sitia G, Gennari L, Guidotti LG, von Andrian UH, Iannacone M. Bisphosphonates target B cells to enhance humoral immune responses. Cell Rep 5(2):323–330CrossRefPubMed Tonti E (2013) Jiménez de Oya N, Galliverti G, Moseman EA, Di Lucia P, Amabile A, Sammicheli S, De Giovanni M, Sironi L, Chevrier N, Sitia G, Gennari L, Guidotti LG, von Andrian UH, Iannacone M. Bisphosphonates target B cells to enhance humoral immune responses. Cell Rep 5(2):323–330CrossRefPubMed
16.
go back to reference Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220–224CrossRefPubMed Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220–224CrossRefPubMed
17.
go back to reference Fraunfelder FT, Fraunfelder FW, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135:219–222CrossRefPubMed Fraunfelder FT, Fraunfelder FW, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135:219–222CrossRefPubMed
18.
go back to reference Mbekeani JN, Slamovits TL, Schwartz BH et al (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117:837–838PubMed Mbekeani JN, Slamovits TL, Schwartz BH et al (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117:837–838PubMed
19.
Metadata
Title
Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data
Authors
F. Xue
V. Goli
P. Petraro
T. McMullan
J. M. Sprafka
E. J. Tchetgen Tchetgen
Publication date
01-10-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4129-6

Other articles of this Issue 10/2017

Osteoporosis International 10/2017 Go to the issue